Cancer Diagnostics: New Developments, Market Growth and Opportunities in the use of Circulating Tumour Cells and Circulating Nucleic Acids

DUBLIN, Sept. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Cancer Diagnostics: New Developments, Market Growth and Opportunities in the use of Circulating Tumour Cells and Circulating Nucleic Acids" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The isolation and characterisation of CTCs and CNAs are two of the fastest growing areas of research in the cancer field. Growth is also being seen in the translation of this research into diagnostic tests. Two new market studies by Biopharm Reports have profiled developments being seen in these fields. Market areas covered include growth, current and next three years; assays, test costs per patient, growth; CTC subpopulations, growth; isolation and detection, growth; suppliers, growth; cell markers, growth; molecular techniques, growth; molecular suppliers, growth; non-molecular techniques, growth; non-molecular suppliers, growth; companion diagnostics, growth; molecular forms, growth; biomarkers, growth; clinical utilities; limitations and purpose.

• Advantages, Disadvantage
• Automated Techniques and Suppliers
• Biomarker Clinical utilities
• Biomarkers
• CTC Subpopulations
• Cancer Stem Cells
• Cancers
• Circulating Nucleic Acids
• Circulating Tumour Cells
• Clinical Drug R&D
• Clinical Trial End-Points
• Clinical Utilities
• Companion Diagnostics
• Current Molecular Forms
• Detection
• Early-Stage Drug Research
• Growth
• Limitations
• Main Cancer Types
• Markers
• Molecular Forms
• Molecular Suppliers
• Molecular Techniques
• Multiplex Methods
• Non-Molecular Suppliers
• Non-Molecular Techniques
• Preclinical Drug R&D
• Samples
• Technique Replacement
• Test Costs

This report presents the findings from two new global studies that profiled 855 end-users, both clinicians and laboratory researchers, relating to the use and investigation of CTCs and CNAs. It covered current activities, recent developments and trends, three-year development plans (2014-2017), as well as new opportunities in diagnostics, research and drug R&D. Its findings provide integrated market information relevant to diagnostic companies, laboratory suppliers and drug developers, on the current and evolving use of CTCs and CNAs in these fields. Biopharm Reports carries out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years. Findings from these studies are based on 'real world' market data.

Key Topics Covered:

1. Background

2. This Report

3. Global Study CTC Study BR1

4. Global Study CTC/CNA BR2

5. Discussion

Companies Mentioned:

• Abbott Molecular
• AccuGenomics
• AdnaGen
• Affymetrix
• Agendia
• Amoy Diagnostics
• Arcxis Biotechnologies
• Arrayit
• Asuragen
• Autogenomics
• Bayer
• BD
• Beckman Coulter
• Biocartis
• Biocept
• BioGenex
• BioHelix
• bioMerieux
• bioTheranostics (AviaraDx)
• Cancer Genetics
• Inc
• Cepheid
• Chronix Biomedical
• Cooperative Diagnostics
• Cytocell
• Da An Gene
• Dako (Agilent)
• DermTech
• Epigenomics
• Gen-Probe
• Hologic
• Illumina
• Invitrogen
• Ipsogen (Qiagen)
• Kreatech Diagnostics
• Luminex
• MDxHealth
• MolecularMD
• Myriad Genetics
• NeoGenomics
• Novartis Diagnostics
• Orion Genomics
• Ortho-Clinical Diagnostics
• OvaGene Oncology
• PrimeraDx
• Qiagen
• Ribomed
• Roche
• SensiGen
• Siemens
• Sysmex
• Thermo Fisher Scientific
• Ventana (Roche)

For more information visit http://www.researchandmarkets.com/research/ffxf8d/cancer

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net